Deal

ABBOTT LABORATORIES acquires Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business)

September 2010 asset purchase ready

Snapshot

ABBOTT LABORATORIES acquired Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business) for $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total) in September 2010. The transaction was structured as all cash (up-front plus deferred payments). Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business) is a Mumbai, India-based Pharmaceuticals — branded generics (India) business.

Acquirer
ABBOTT LABORATORIES
Target
Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business)
Value
$2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total)
Date
September 2010
Type
asset purchase
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
ABBOTT LABORATORIES acquires Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business)
Deal value
$2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total)
Sector
Pharmaceuticals — branded generics (India)
Date
September 2010
VectorShift
Made on VectorShift

About this deal

ABBOTT LABORATORIES acquired Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business) for $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total), a transaction completed in September 2010, structured as all cash (up-front plus deferred payments). The deal was a asset purchase.

Piramal Healthcare Solutions (Piramal Healthcare's Healthcare Solutions business) operates in Pharmaceuticals — branded generics (India), is based in Mumbai, India. Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution.

Propels Abbott to the top position in India with pharmaceutical sales expected to exceed $2.5 billion by 2020, establishing Abbott as the leading pharmaceutical company in India.

Top market position in the fast-growing Indian pharmaceutical market. Integrated into Abbott's Established Products / pharmaceutical business in India

Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press releaseSEC filing Last updated

See how VectorShift works for your firm

Request Demo